References
- Griffiths CE, Dubertret L, Ellis CN, Finlay AY, Finzi AF, Ho VC, Ciclosporin in psoriasis clinical practice: An international consensus statement. Br J Dermatol. 2004;150(suppl 67):11–23.
- Griffiths CE, Katsambas A, Dijkmans BA, Finlay AY, Ho VC, Johnston A, Update on the use of ciclosporin in immune-mediated dermatoses. Br J Dermatol. 2006;155(suppl 2):1–16.
- Jorga A, Holt DW, Johnston A. Therapeutic drug monitoring of cyclosporine. Transplant Proc. 2004;36(2 suppl):396S–403S.
- Johnston A, David OJ, Cooney GP. Pharmacokinetic validation of Neoral absorption profiling. Transplant Proc. 2000;32:53S.
- Pescovitz MD, Barbeito R, for the Simulect US01 Study Group. Two-hour post-dose cyclosporine level is a better predictor than trough level of acute rejection of renal allografts. Clin Transplant. 2002;16:378–382.
- Trompeter R, Fitzpatrick M, Hutchinson C, Johnston A. Longitudinal evaluation of the pharmacokinetics of cyclosporin microemulsion (Neoral) in pediatric renal transplant recipients and assessment of C2 level as a marker for absorption. Pediatr Transplant. 2003;7(4):282–288.
- Di Paolo S, Teutonico A, Stallone G, Infante B, Schena A, Grandaliano G, Cyclosporin exposure correlates with 1 year graft function and histological damage in renal transplanted patients. Nephrol Dial Transplant. 2004;19:2107–2111.
- Levy G, Burra P, Cavallari A, Duvoux C, Lake J, Mayer AD, Improved clinical outcomes for liver transplant recipients using cyclosporine monitoring based on 2-hr post-dose levels (C2). Transplantation. 2002;73(6):953–959.
- Johnston A, Chusney G, Schütz E, Oellerich M, Lee TD, Holt DW. Monitoring cyclosporin in blood: Between-assay differences at trough and 2 hours post-dose (C2). Ther Drug Monit. 2003;25(2):167–173.
- Dominguez J, Fuenzalida D, Norambuena, Pais E, Cortes Monroy G, Llanos R. C2 monitoring of cyclosporine in stable renal transplant patients results in lower costs and improved renal function. Transplantation Proc. 2005;37:1583–1585.
- Einecke G, Schutz M, Mai I, Fritsche L, Giessing M, Glander P, Limitations of C2 monitoring in renal transplant recipients. Nephrol Dial Transplant. 2005;20(7):1463–1470.
- Stefoni S, Midtvedt K, Cole E, Thervet E, Cockfield S, Buchler M, Efficacy and safety outcomes among de novo renal transplant recipients managed by C2 monitoring of cyclosporine A microemulsion: Results of a 12-month randomized, multicenter study. Transplantation. 2005;79(5):577–583.
- Midtvedt K, Fauchald P, Bergan S, Høieggen A, Hallan S, Svarstad E, C2 monitoring in maintenance renal transplant recipients: Is it worthwhile? Transplantation. 2003;76(8):1236–1238.
- National Institute for Health and Clinical Excellence (NICE) Clinical Guideline 76. Medicines adherence: Involving patients in decisions about prescribing medicines and supporting adherence. 2009 Jan [last accessed 2009 December 12]. Available from: http://www.nice.org.uk/nicemedia/pdf/CG76NICEGuideline.pdf.
- Koo J. A randomized, double-blind study comparing the efficacy, safety and optimal dose of two formulations of cyclosporin, Neoral and Sandimmun, in patients with severe psoriasis. OLP302 Study Group. Br J Dermatol. 1998;139(1):88–95.
- Higgins RM, Kanji H, Hernon M, Harrison P, Lam FT, Kashi SH. Cyclosporine dose reduction in stable renal transplant patients with high C2 level: Simplified method of single C2 measurement and individualization of C0 target. Transpl Int. 2005;18(7):806–810.
- Dominguez J, Fuenzalida D, Norambuena R, Pais E, Cortes Monroy G, Llanos R. C2 monitoring of cyclosporine in stable renal transplant patients results in lower costs and improved renal function. Transplant Proc. 2005;37(3):1583–1585.